A Geriatric Assessment Electronic Platform for Older Patients With Cancer (eGAP - Electronic Geriatric Assessment Platform)
NCT ID: NCT04824859
Last Updated: 2026-01-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
21 participants
INTERVENTIONAL
2021-12-07
2023-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Supportive Care Intervention for Older Caregivers of Older Adults with Advanced Cancer
NCT05244915
Technology to Assess Vulnerable Older Adults With Cancer and Their Caregivers
NCT02041416
Geriatric Assessment and Promotores (GAP) Pilot Feasibility Study
NCT06125145
Understanding Needs of Older Patients Prior to Starting Cancer Treatment
NCT07225920
Comprehensive Health Assessment for my Cancer Treatment Plan
NCT05499975
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental
The eGAP consists of validated questionnaires that are used to assess health status of older adults with cancer. Based on patient responses, tailored recommendations will be provided.
Behavioral
eGAP that allows patients to complete validated questionnaires, and these questionnaires will be summarized and recommendations provided to the treating team
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Behavioral
eGAP that allows patients to complete validated questionnaires, and these questionnaires will be summarized and recommendations provided to the treating team
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a diagnosis of cancer
* Able to provide informed consent
* English-speaking (because the platform is currently in English)
* Age ≥21 years
* Selected by patient when asked if there is a "family member, partner, friend, or caregiver with whom you discuss or who can be helpful in health-related matters".
* Able to provide informed consent
* English-speaking
* Oncologists, APPs, and nurses who care for the patient
Exclusion Criteria
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Rochester
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kah Poh Loh
Associate Professor - Department of Medicine, Hematology/Oncology (SMD)
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kah Poh Loh
Role: PRINCIPAL_INVESTIGATOR
University of Rochester
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Rochester
Rochester, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UCCS21026
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.